{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:47:34Z","timestamp":1792802854173,"version":"4.5.0"},"reference-count":151,"publisher":"Elsevier","isbn-type":[{"value":"9780443158223","type":"print"}],"license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"DOI":"10.1016\/bs.apcsb.2023.02.001","type":"book-chapter","created":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T09:48:18Z","timestamp":1678960098000},"page":"21-55","source":"Crossref","is-referenced-by-count":28,"title":["Cyclin-dependent kinases in cancer: Role, regulation, and therapeutic targeting"],"prefix":"10.1016","author":[{"given":"Ashna","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunjan","family":"Dagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana Q.","family":"Sadida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara K.","family":"Almarzooqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheema","family":"Hashem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahab","family":"Uddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muzafar A.","family":"Macha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammira S. Al-Shabeeb","family":"Akil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tej K.","family":"Pandita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajaz A.","family":"Bhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayank","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/bs.apcsb.2023.02.001_bb0010","doi-asserted-by":"crossref","first-page":"6623","DOI":"10.1128\/MCB.16.12.6623","article-title":"Identification of a cyclin-cdk2 recognition motif present in substrates and p21-like cyclin-dependent kinase inhibitors","volume":"16","author":"Adams","year":"1996","journal-title":"Molecular and Cellular Biology"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0015","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s12282-018-0894-0","article-title":"CDKN2A\/P16INK4A variants association with breast cancer and their in-silico analysis","volume":"26","author":"Aftab","year":"2019","journal-title":"Breast Cancer"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0020","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/35024111","article-title":"TFIIH is negatively regulated by cdk8-containing mediator complexes","volume":"407","author":"Akoulitchev","year":"2000","journal-title":"Nature"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb756","series-title":"An overview of the cell cycle","article-title":"Molecular biology of the cell","author":"Alberts","year":"2002"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0025","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/ncb1284","article-title":"Cdc2-cyclin E complexes regulate the G1\/S phase transition","volume":"7","author":"Aleem","year":"2005","journal-title":"Nature Cell Biology"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0030","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1093\/neuonc\/noz126.000","article-title":"CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas","volume":"21","author":"Appay","year":"2019","journal-title":"Neuro-Oncology"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0035","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nrm2653","article-title":"Polo-like kinases: Conservation and divergence in their functions and regulation","volume":"10","author":"Archambault","year":"2009","journal-title":"Nature Reviews. Molecular Cell Biology"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0040","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1158\/0008-5472.CAN-15-1070","article-title":"The CDK9 inhibitor dinaciclib exerts potent apoptotic and antitumor effects in preclinical models of MLL-rearranged acute myeloid leukemia","volume":"76","author":"Baker","year":"2016","journal-title":"Cancer Research"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0045","doi-asserted-by":"crossref","first-page":"7661","DOI":"10.1158\/0008-5472.CAN-06-1098","article-title":"A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4\/6","volume":"66","author":"Baughn","year":"2006","journal-title":"Cancer Research"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0050","doi-asserted-by":"crossref","first-page":"4760","DOI":"10.1158\/1078-0432.CCR-15-1185","article-title":"FDA approval: Palbociclib for the treatment of postmenopausal patients with estrogen receptor-positive, HER2-negative metastatic breast cancer","volume":"21","author":"Beaver","year":"2015","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0055","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1002\/cam4.2023","article-title":"Retinoblastoma mutation predicts poor outcomes in advanced non small cell lung cancer","volume":"8","author":"Bhateja","year":"2019","journal-title":"Cancer Medicine"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0060","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1517\/13543784.2013.789859","article-title":"Cyclin-dependent kinase inhibitor therapy for hematologic malignancies","volume":"22","author":"Bose","year":"2013","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0065","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood-2006-05-020735","article-title":"Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia","volume":"109","author":"Byrd","year":"2006","journal-title":"Blood"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0070","unstructured":"Carrick Therapeutics Limited, 2021. A modular, multipart, multiarm, open-label, phase I\/II study to evaluate the safety and tolerability of CT7001 alone and in combination with anti-cancer treatments in patients with advanced malignancies (Clinical trial registration No. NCT03363893). clinicaltrials.gov."},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0075","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S1534-5807(03)00193-X","article-title":"Polo-like kinase 1 regulates Nlp, a centrosome protein involved in microtubule nucleation","volume":"5","author":"Casenghi","year":"2003","journal-title":"Developmental Cell"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0080","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/sj.onc.1207973","article-title":"The anaphase-promoting complex: A key factor in the regulation of cell cycle","volume":"24","author":"Castro","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0085","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1038\/bjc.2014.565","article-title":"A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177","volume":"111","author":"Chen","year":"2014","journal-title":"British Journal of Cancer"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0090","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S1534-5807(02)00258-7","article-title":"CP110, a cell cycle-dependent CDK substrate, regulates centrosome duplication in human cells","volume":"3","author":"Chen","year":"2002","journal-title":"Developmental Cell"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0095","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1158\/1535-7163.MCT-16-0300","article-title":"Spectrum and degree of CDK drug interactions predicts clinical performance","volume":"15","author":"Chen","year":"2016","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0100","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.1128\/MCB.16.9.4673","article-title":"Cyclin-binding motifs are essential for the function of p21CIP1","volume":"16","author":"Chen","year":"1996","journal-title":"Molecular and Cellular Biology"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0105","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.cell.2014.10.024","article-title":"CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer","volume":"159","author":"Chipumuro","year":"2014","journal-title":"Cell"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0110","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.ccr.2012.09.015","article-title":"The requirement for cyclin D function in tumor maintenance","volume":"22","author":"Choi","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0115","doi-asserted-by":"crossref","unstructured":"Cidado, J., Boiko, S., Proia, T., Ferguson, D., Criscione, S.W., San Martin, M., Pop-Damkov, P., Su, N., Roamio Franklin, V.N., Sekhar Reddy Chilamakuri, C., D\u2019Santos, C.S., Shao, W., Saeh, J.C., Koch, R., Weinstock, D.M., Zinda, M., Fawell, S.E., Drew, L., 2020. AZD4573 is a highly selective CDK9 inhibitor that suppresses MCL-1 and induces apoptosis in hematologic cancer cells. Clinical Cancer Research 26, 922\u2013934. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1853","DOI":"10.1158\/1078-0432.CCR-19-1853"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0120","series-title":"The cell: A molecular approach","author":"Cooper","year":"2000"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0125","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/ncb813","article-title":"Distinct roles for cyclins E and A during DNA replication complex assembly and activation","volume":"4","author":"Coverley","year":"2002","journal-title":"Nature Cell Biology"},{"issue":"Pt. 11","key":"10.1016\/bs.apcsb.2023.02.001_bb0130","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1242\/jcs.113.11.1929","article-title":"Chromatin-bound Cdc6 persists in S and G2 phases in human cells, while soluble Cdc6 is destroyed in a cyclin A-cdk2 dependent process","volume":"113","author":"Coverley","year":"2000","journal-title":"Journal of Cell Science"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0135","unstructured":"Cyclacel Pharmaceuticals, Inc., 2021. A phase IIb randomized study of oral seliciclib in patients with previously treated non-small cell lung cancer (Clinical trial registration No. NCT00372073). clinicaltrials.gov."},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0140","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a015834","article-title":"Cytokinesis in animal cells","volume":"7","author":"D\u2019Avino","year":"2015","journal-title":"Cold Spring Harbor Perspectives in Biology"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0145","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nchembio.1952","article-title":"A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease","volume":"11","author":"Dale","year":"2015","journal-title":"Nature Chemical Biology"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0150","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3389\/fcell.2018.00171","article-title":"Molecular and in vivo functions of the CDK8 and CDK19 kinase modules","volume":"6","author":"Dannappel","year":"2019","journal-title":"Frontiers in Cell and Development Biology"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0155","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.tcb.2010.05.002","article-title":"Emerging links between CDK cell cycle regulators and Wnt signaling","volume":"20","author":"Davidson","year":"2010","journal-title":"Trends in Cell Biology"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0160","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0969-2126(01)00598-6","article-title":"Inhibitor binding to active and inactive CDK2: The crystal structure of CDK2-cyclin A\/indirubin-5-sulphonate","volume":"9","author":"Davies","year":"2001","journal-title":"Structure"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0165","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1038\/onc.2008.74","article-title":"Cyclin A\/cdk2 coordinates centrosomal and nuclear mitotic events","volume":"27","author":"de Boer","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0170","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1083\/jcb.153.1.121","article-title":"Cyclin A is destroyed in prometaphase and can delay chromosome alignment and anaphase","volume":"153","author":"den Elzen","year":"2001","journal-title":"The Journal of Cell Biology"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0175","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s10571-007-9242-1","article-title":"An unusual member of the Cdk family: Cdk5","volume":"28","author":"Dhariwala","year":"2008","journal-title":"Cellular and Molecular Neurobiology"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0180","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1080\/15384101.2021.1938813","article-title":"Activation of CDC25A phosphatase is limited by CDK2\/cyclin A-mediated feedback inhibition","volume":"20","author":"Ditano","year":"2021","journal-title":"Cell Cycle"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0185","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.semcdb.2010.08.005","article-title":"Still entangled: Assembly of the central spindle by multiple microtubule modulators","volume":"21","author":"Douglas","year":"2010","journal-title":"Seminars in Cell & Developmental Biology"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0190","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0092-8674(91)90582-J","article-title":"The cdc25 protein contains an intrinsic phosphatase activity","volume":"67","author":"Dunphy","year":"1991","journal-title":"Cell"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0195","doi-asserted-by":"crossref","first-page":"5543","DOI":"10.1007\/s00018-021-03878-8","article-title":"CDK9 keeps RNA polymerase II on track","volume":"78","author":"Egloff","year":"2021","journal-title":"Cellular and Molecular Life Sciences"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0200","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3390\/cancers14020293","article-title":"The renaissance of cyclin dependent kinase inhibitors","volume":"14","author":"Ettl","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0205","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/349808a0","article-title":"Fission yeast p107wee1 mitotic inhibitor is a tyrosine\/serine kinase","volume":"349","author":"Featherstone","year":"1991","journal-title":"Nature"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0210","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1083\/jcb.152.6.1267","article-title":"Cyclin E uses Cdc6 as a chromatin-associated receptor required for DNA replication","volume":"152","author":"Furstenthal","year":"2001","journal-title":"The Journal of Cell Biology"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0215","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1093\/annonc\/mdy452","article-title":"Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach","volume":"29","author":"Galot","year":"2018","journal-title":"Annals of Oncology"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0220","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1083\/jcb.153.1.137","article-title":"Anaphase-promoting complex\/cyclosome-dependent proteolysis of human cyclin A starts at the beginning of mitosis and is not subject to the spindle assembly checkpoint","volume":"153","author":"Geley","year":"2001","journal-title":"The Journal of Cell Biology"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0225","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.breast.2021.07.017","article-title":"Efficacy and safety of palbociclib in patients with estrogen receptor\u2013positive\/human epidermal growth factor receptor 2\u2013negative advanced breast cancer with preexisting conditions: A post hoc analysis of PALOMA-2","volume":"59","author":"Gelmon","year":"2021","journal-title":"The Breast"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0230","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature14664","article-title":"Comprehensive genomic profiles of small cell lung cancer","volume":"524","author":"George","year":"2015","journal-title":"Nature"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0235","unstructured":"Georgetown University, 2020. A phase I study of the CDK4\/6 inhibitor PD-0332991, 5-fluorouracil, and oxaliplatin in patients with advanced solid tumor malignancies (Clinical trial registration No. NCT01522989). clinicaltrials.gov."},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0240","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/blood-2016-10-748210","article-title":"Efficacy and safety of dinaciclib vs ofatumumab in patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"129","author":"Ghia","year":"2017","journal-title":"Blood"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0245","doi-asserted-by":"crossref","first-page":"5220","DOI":"10.1038\/sj.onc.1209615","article-title":"RB and cell cycle progression","volume":"25","author":"Giacinti","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0250","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ccell.2016.02.006","article-title":"Overcoming therapeutic resistance in HER2-positive breast cancers with CDK4\/6 inhibitors","volume":"29","author":"Goel","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0255","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0260","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1111\/febs.13166","article-title":"The spindle checkpoint and chromosome segregation in meiosis","volume":"282","author":"Gorbsky","year":"2015","journal-title":"The FEBS Journal"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0265","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/342039a0","article-title":"Tyrosine phosphorylation of the fission yeast cdc2+ protein kinase regulates entry into mitosis","volume":"342","author":"Gould","year":"1989","journal-title":"Nature"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0270","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ctrv.2016.03.002","article-title":"Targeting CDK4\/6 in patients with cancer","volume":"45","author":"Hamilton","year":"2016","journal-title":"Cancer Treatment Reviews"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0275","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0005976","article-title":"Plk1-dependent recruitment of gamma-tubulin complexes to mitotic centrosomes involves multiple PCM components","volume":"4","author":"Haren","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0280","doi-asserted-by":"crossref","first-page":"10867","DOI":"10.1073\/pnas.89.22.10867","article-title":"Neuronal cdc2-like kinase: A cdc2-related protein kinase with predominantly neuronal expression","volume":"89","author":"Hellmich","year":"1992","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0285","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/sj.emboj.7600554","article-title":"The structure of cyclin E1\/CDK2: Implications for CDK2 activation and CDK2-independent roles","volume":"24","author":"Honda","year":"2005","journal-title":"The EMBO Journal"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0290","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for HR-positive, advanced breast cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0295","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1158\/1538-7445.AM2019-4421","article-title":"Abstract 4421: SY-5609, an orally available selective CDK7 inhibitor demonstrates broad antitumor activity in vivo","volume":"79","author":"Hu","year":"2019","journal-title":"Cancer Research"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0300","doi-asserted-by":"crossref","first-page":"16235","DOI":"10.1074\/jbc.M909040199","article-title":"Inhibition of Mcm4,6,7 helicase activity by phosphorylation with cyclin A\/Cdk2","volume":"275","author":"Ishimi","year":"2000","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0305","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1101\/gad.851100","article-title":"Structural basis of inhibition of CDK\u2013cyclin complexes by INK4 inhibitors","volume":"14","author":"Jeffrey","year":"2000","journal-title":"Genes & Development"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0310","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.tibs.2013.03.004","article-title":"Tracking spindle checkpoint signals from kinetochores to APC\/C","volume":"38","author":"Jia","year":"2013","journal-title":"Trends in Biochemical Sciences"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0315","doi-asserted-by":"crossref","first-page":"C091","DOI":"10.1158\/1535-7163.TARG-19-C091","article-title":"Abstract C091: Preclinical evaluation of PK, PD, and antitumor activity of the oral, non-covalent, potent and highly selective CDK7 inhibitor, SY-5609, provides rationale for clinical development in multiple solid tumor indications","volume":"18","author":"Johannessen","year":"2019","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0320","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nm.2377","article-title":"Compromised CDK1 activity sensitizes BRCA-proficient cancers to parp inhibition","volume":"17","author":"Johnson","year":"2011","journal-title":"Nature Medicine"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0325","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1038\/leu.2012.144","article-title":"The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells","volume":"26","author":"Johnson","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0330","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1471-2407-14-32","article-title":"Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4\/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells","volume":"14","author":"Kang","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0335","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccell.2018.03.023","article-title":"CDK4\/6 inhibitors: The mechanism of action may not be as simple as once thought","volume":"34","author":"Klein","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0340","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1091\/mbc.3.11.1279","article-title":"Identification of the domains in cyclin A required for binding to, and activation of, p34cdc2 and p32cdk2 protein kinase subunits","volume":"3","author":"Kobayashi","year":"1992","journal-title":"Molecular Biology of the Cell"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0345","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1021\/acsmedchemlett.5b00278","article-title":"Development of a Potent, Specific CDK8 Kinase Inhibitor Which Phenocopies CDK8\/19 Knockout Cells","volume":"7","author":"Koehler","year":"2016","journal-title":"ACS Medicinal Chemistry Letters"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0350","doi-asserted-by":"crossref","first-page":"14803","DOI":"10.18632\/oncotarget.7543","article-title":"The CDK4\/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma","volume":"7","author":"Ku","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0355","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1126\/science.273.5280.1377","article-title":"Purification and molecular cloning of Plx1, a Cdc25-regulatory kinase from Xenopus egg extracts","volume":"273","author":"Kumagai","year":"1996","journal-title":"Science"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0360","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1182\/blood.V120.21.76.76","article-title":"Phase 1\/2 trial of a novel CDK inhibitor dinaciclib (SCH727965) in patients with relapsed multiple myeloma demonstrates encouraging single agent activity","volume":"120","author":"Kumar","year":"2012","journal-title":"Blood"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0365","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/nature13393","article-title":"Targeting transcription regulation in cancer with a covalent CDK7 inhibitor","volume":"511","author":"Kwiatkowski","year":"2014","journal-title":"Nature"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0370","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1016\/j.ejca.2010.08.001","article-title":"Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies","volume":"46","author":"Le Tourneau","year":"2010","journal-title":"European Journal of Cancer"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0375","first-page":"1140","article-title":"CDK9 inhibitor CDKI-73 is synergetic lethal with PARP inhibitor olaparib in BRCA1 wide-type ovarian cancer","volume":"10","author":"Li","year":"2020","journal-title":"American Journal of Cancer Research"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0380","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1158\/1535-7163.MCT-12-0562","article-title":"Cdk4\/6 inhibition induces epithelial-mesenchymal transition and enhances invasiveness in pancreatic cancer cells","volume":"11","author":"Liu","year":"2012","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0385","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s10637-011-9641-5","article-title":"In vitro antitumor mechanism of a novel cyclin-dependent kinase inhibitor CDKI-83","volume":"30","author":"Liu","year":"2012","journal-title":"Investigational New Drugs"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2018.02.052","article-title":"An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics","volume":"173","author":"Liu","year":"2018","journal-title":"Cell"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0395","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/3855","article-title":"Cyclin A1 is required for meiosis in the male mouse","volume":"20","author":"Liu","year":"1998","journal-title":"Nature Genetics"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0400","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/0014-5793(92)80844-7","article-title":"Cyclin A-Cys41 does not undergo cell cycle-dependent degradation in Xenopus extracts","volume":"306","author":"Lorca","year":"1992","journal-title":"FEBS Letters"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0405","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1042\/BJ20100284","article-title":"How protein kinases coordinate mitosis in animal cells","volume":"435","author":"Ma","year":"2011","journal-title":"The Biochemical Journal"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0410","first-page":"311","article-title":"Cyclin A message stability varies with the cell cycle","volume":"8","author":"Maity","year":"1997","journal-title":"Cell Growth & Differentiation"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0415","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1021\/acsmedchemlett.6b00022","article-title":"2,8-Disubstituted-1,6-naphthyridines and 4,6-disubstituted-isoquinolines with potent, selective affinity for CDK8\/19","volume":"7","author":"Mallinger","year":"2016","journal-title":"ACS Medicinal Chemistry Letters"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0420","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3109\/10409238.2010.541420","article-title":"State of the APC\/C: Organization, function, and structure","volume":"46","author":"McLean","year":"2011","journal-title":"Critical Reviews in Biochemistry and Molecular Biology"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0425","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.clbc.2013.10.016","article-title":"Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer","volume":"14","author":"Mita","year":"2014","journal-title":"Clinical Breast Cancer"},{"issue":"4","key":"10.1016\/bs.apcsb.2023.02.001_bb759","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1111\/febs.12685","article-title":"Regulation of \u03b1-endosulfine, an inhibitor of protein phosphatase 2A, by multisite phosphorylation","volume":"281","author":"Mochida","year":"2014","journal-title":"The FEBS Journal"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0430","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1126\/science.1195689","article-title":"Greatwall phosphorylates an inhibitor of protein phosphatase 2A that is essential for mitosis","volume":"330","author":"Mochida","year":"2010","journal-title":"Science"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0435","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/374131a0","article-title":"Principles of CDK regulation","volume":"374","author":"Morgan","year":"1995","journal-title":"Nature"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0440","series-title":"The cell cycle: Principles of control, Primers in biology","author":"Morgan","year":"2007"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0445","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/ng0197-83","article-title":"Delayed early embryonic lethality following disruption of the murine cyclin A2 gene","volume":"15","author":"Murphy","year":"1997","journal-title":"Nature Genetics"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb760","article-title":"The cell cycle: An introduction","author":"Murray","year":"1993","journal-title":"Molecular Reproduction & Development"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0450","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/nrm2163","article-title":"The spindle-assembly checkpoint in space and time","volume":"8","author":"Musacchio","year":"2007","journal-title":"Nature Reviews. Molecular Cell Biology"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0455","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.ccell.2017.03.011","article-title":"Transcriptional dependencies in diffuse intrinsic pontine glioma","volume":"31","author":"Nagaraja","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0460","unstructured":"National Cancer Institute (NCI), 2022. A phase 1 trial of the combination of the heat shock protein-90 (HSP90) inhibitor onalespib (AT13387) and the cyclin-dependent kinase (CDK) inhibitor AT7519M in patients with advanced solid tumors (Clinical trial registration No. NCT02503709). clinicaltrials.gov."},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0465","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/1479-5876-11-259","article-title":"A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies","volume":"11","author":"Nemunaitis","year":"2013","journal-title":"Journal of Translational Medicine"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0470","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.26","article-title":"Treating cancer with selective CDK4\/6 inhibitors","volume":"13","author":"O\u2019Leary","year":"2016","journal-title":"Nature Reviews. Clinical Oncology"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0475","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0092-8674(00)00093-3","article-title":"Nucleophosmin\/B23 is a target of CDK2\/cyclin E in centrosome duplication","volume":"103","author":"Okuda","year":"2000","journal-title":"Cell"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0480","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.chembiol.2019.02.012","article-title":"Development of a selective CDK7 covalent inhibitor reveals predominant cell-cycle phenotype","volume":"26","author":"Olson","year":"2019","journal-title":"Cell Chemical Biology"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0485","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1002\/j.1460-2075.1992.tb05135.x","article-title":"Cyclin A is required at two points in the human cell cycle","volume":"11","author":"Pagano","year":"1992","journal-title":"The EMBO Journal"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0490","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1182\/blood.V91.2.458","article-title":"Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol","volume":"91","author":"Parker","year":"1998","journal-title":"Blood"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0495","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1126\/science.1384126","article-title":"Inactivation of the p34cdc2-cyclin B complex by the human WEE1 tyrosine kinase","volume":"257","author":"Parker","year":"1992","journal-title":"Science"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0500","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1158\/1535-7163.MCT-10-0324","article-title":"Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor","volume":"9","author":"Parry","year":"2010","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0505","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nature14904","article-title":"Mediator kinase inhibition further activates super-enhancer-associated genes in AML","volume":"526","author":"Pelish","year":"2015","journal-title":"Nature"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0510","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1747-1028-2-12","article-title":"Cdc25 and Wee1: Analogous opposites?","volume":"2","author":"Perry","year":"2007","journal-title":"Cell Division"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0515","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1093\/emboj\/18.2.396","article-title":"Phosphorylation of mammalian CDC6 by cyclin A\/CDK2 regulates its subcellular localization","volume":"18","author":"Petersen","year":"1999","journal-title":"The EMBO Journal"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0520","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.ygyno.2020.01.038","article-title":"CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes","volume":"157","author":"Petersen","year":"2020","journal-title":"Gynecologic Oncology"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0525","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/ncb954","article-title":"Building a cell cycle oscillator: Hysteresis and bistability in the activation of Cdc2","volume":"5","author":"Pomerening","year":"2003","journal-title":"Nature Cell Biology"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0530","first-page":"335","article-title":"Cyclin B1 and CDK1: Nuclear localization and upstream regulators","volume":"5","author":"Porter","year":"2003","journal-title":"Progress in Cell Cycle Research"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0535","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1080\/15384101.2018.1491236","article-title":"CDK1 inhibition sensitizes normal cells to DNA damage in a cell cycle dependent manner","volume":"17","author":"Prevo","year":"2018","journal-title":"Cell Cycle"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0540","doi-asserted-by":"crossref","first-page":"6173","DOI":"10.1158\/1078-0432.CCR-13-1675","article-title":"Dual CDK4\/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma","volume":"19","author":"Rader","year":"2013","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0545","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1158\/1078-0432.CCR-04-2264","article-title":"In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202","volume":"11","author":"Raynaud","year":"2005","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2018.03.035","article-title":"Oncogenic signaling pathways in the cancer genome atlas","volume":"173","author":"Sanchez-Vega","year":"2018","journal-title":"Cell"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0555","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1038\/emboj.2009.173","article-title":"The life and miracles of kinetochores","volume":"28","author":"Santaguida","year":"2009","journal-title":"The EMBO Journal"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0560","doi-asserted-by":"crossref","first-page":"10453","DOI":"10.1073\/pnas.95.18.10453","article-title":"Substrate recruitment to cyclin-dependent kinase 2 by a multipurpose docking site on cyclin A","volume":"95","author":"Schulman","year":"1998","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0565","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/374280a0","article-title":"Association of Cdk-activating kinase subunits with transcription factor TFIIH","volume":"374","author":"Serizawa","year":"1995","journal-title":"Nature"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0570","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1200\/JCO.2005.03.7689","article-title":"Cyclin-dependent kinase pathways as targets for cancer treatment","volume":"24","author":"Shapiro","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0575","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1101\/gad.11.11.1464","article-title":"Cyclin E-CDK2 is a regulator of p27Kip1","volume":"11","author":"Sheaff","year":"1997","journal-title":"Genes & Development"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0580","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1101\/gad.9.10.1149","article-title":"Inhibitors of mammalian G1 cyclin-dependent kinases","volume":"9","author":"Sherr","year":"1995","journal-title":"Genes & Development"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0585","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1101\/gad.13.12.1501","article-title":"CDK inhibitors: Positive and negative regulators of G1-phase progression","volume":"13","author":"Sherr","year":"1999","journal-title":"Genes & Development"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0590","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1101\/gad.1256504","article-title":"Living with or without cyclins and cyclin-dependent kinases","volume":"18","author":"Sherr","year":"2004","journal-title":"Genes & Development"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0595","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1101\/gad.13.18.2375","article-title":"Cullin-3 targets cyclin E for ubiquitination and controls S phase in mammalian cells","volume":"13","author":"Singer","year":"1999","journal-title":"Genes & Development"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0600","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4161\/cc.11.1.18775","article-title":"An integrated view of cyclin E function and regulation","volume":"11","author":"Siu","year":"2012","journal-title":"Cell Cycle"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0605","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/j.1460-2075.1994.tb06296.x","article-title":"Destruction of Xenopus cyclins A and B2, but not B1, requires binding to p34cdc2","volume":"13","author":"Stewart","year":"1994","journal-title":"The EMBO Journal"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0610","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/35095076","article-title":"Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line","volume":"413","author":"Strohmaier","year":"2001","journal-title":"Nature"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0615","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1083\/jcb.200102093","article-title":"Checkpoint inhibition of the APC\/C in HeLa cells is mediated by a complex of BUBR1, BUB3, CDC20, and MAD2","volume":"154","author":"Sudakin","year":"2001","journal-title":"The Journal of Cell Biology"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0620","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.ccell.2021.03.010","article-title":"Targeting cell-cycle machinery in cancer","volume":"39","author":"Suski","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0625","unstructured":"Syros Pharmaceuticals, 2022. A phase 1 study of SY 5609, an oral, selective CDK7 inhibitor, in adult patients with select advanced solid tumors (Clinical trial registration No. NCT04247126). clinicaltrials.gov."},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0630","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1097\/JTO.0b013e3182a46c0c","article-title":"CDKN2A\/p16 inactivation mechanisms and their relationship to smoke exposure and molecular features in non-small-cell lung cancer","volume":"8","author":"Tam","year":"2013","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0635","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.molcel.2019.03.020","article-title":"Cyclin D-Cdk4,6 drives cell-cycle progression via the retinoblastoma protein's C-terminal helix","volume":"74","author":"Topacio","year":"2019","journal-title":"Molecular Cell"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0640","doi-asserted-by":"crossref","first-page":"947","DOI":"10.7150\/jca.14441","article-title":"Effects of CDK4\/6 inhibition in hormone receptor-positive\/human epidermal growth factor receptor 2-negative breast cancer cells with acquired resistance to paclitaxel","volume":"7","author":"Trap\u00e9","year":"2016","journal-title":"Journal of Cancer"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0645","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/21831","article-title":"Sister-chromatid separation at anaphase onset is promoted by cleavage of the cohesin subunit Scc1","volume":"400","author":"Uhlmann","year":"1999","journal-title":"Nature"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0650","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1158\/1535-7163.MCT-19-0695","article-title":"Preclinical activity of ribociclib in squamous cell carcinoma of the head and neck","volume":"19","author":"van Caloen","year":"2020","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0655","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1158\/1078-0432.CCR-16-0493","article-title":"FDA approval of palbociclib in combination with fulvestrant for the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer","volume":"22","author":"Walker","year":"2016","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0660","doi-asserted-by":"crossref","first-page":"375","DOI":"10.18632\/oncotarget.1568","article-title":"A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine","volume":"5","author":"Walsby","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0665","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.3390\/cells10123327","article-title":"Regulation of cell cycle progression by growth factor-induced cell signaling","volume":"10","author":"Wang","year":"2021","journal-title":"Cell"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0670","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.devcel.2014.03.012","article-title":"Cyclin B1\/Cdk1 coordinates mitochondrial respiration for cell-cycle G2\/M progression","volume":"29","author":"Wang","year":"2014","journal-title":"Developmental Cell"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0675","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13008-018-0040-6","article-title":"The functional diversity of Aurora kinases: A comprehensive review","volume":"13","author":"Willems","year":"2018","journal-title":"Cell Division"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0680","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1158\/1078-0432.CCR-16-1114","article-title":"Dual ALK and CDK4\/6 inhibition demonstrates synergy against neuroblastoma","volume":"23","author":"Wood","year":"2017","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0685","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.7150\/thno.25487","article-title":"Blocking CDK1\/PDK1\/\u03b2-catenin signaling by CDK1 inhibitor RO3306 increased the efficacy of sorafenib treatment by targeting cancer stem cells in a preclinical model of hepatocellular carcinoma","volume":"8","author":"Wu","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0690","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nrm3149","article-title":"Phosphatases: Providing safe passage through mitotic exit","volume":"12","author":"Wurzenberger","year":"2011","journal-title":"Nature Reviews. Molecular Cell Biology"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0695","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1080\/1042819021000006295","article-title":"Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China","volume":"43","author":"Xiao","year":"2002","journal-title":"Leukemia & Lymphoma"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0700","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1007\/s00018-002-8510-y","article-title":"Cyclin A in cell cycle control and cancer","volume":"59","author":"Yam","year":"2002","journal-title":"Cellular and Molecular Life Sciences"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0705","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1101\/gad.12.14.2131","article-title":"Control of cyclin B1 localization through regulated binding of the nuclear export factor CRM1","volume":"12","author":"Yang","year":"1998","journal-title":"Genes & Development"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0710","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.cell.2007.08.048","article-title":"p31comet blocks Mad2 activation through structural mimicry","volume":"131","author":"Yang","year":"2007","journal-title":"Cell"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0715","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.leukres.2015.10.010","article-title":"Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia","volume":"39","author":"Zeidner","year":"2015","journal-title":"Leukemia Research"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0720","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ccell.2019.11.003","article-title":"CDK7 inhibition potentiates genome instability triggering antitumor immunity in small cell lung cancer","volume":"37","author":"Zhang","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0725","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2018.09.051","article-title":"Targeting CDK9 reactivates epigenetically silenced genes in cancer","volume":"175","author":"Zhang","year":"2018","journal-title":"Cell"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0730","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1158\/1535-7163.MCT-14-0387","article-title":"Antiproliferative effects of CDK4\/6 inhibition in CDK4-amplified human liposarcoma in vitro and in vivo","volume":"13","author":"Zhang","year":"2014","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0735","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1101\/gad.827700","article-title":"NPAT links cyclin E\u2013Cdk2 to the regulation of replication-dependent histone gene transcription","volume":"14","author":"Zhao","year":"2000","journal-title":"Genes & Development"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0740","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12885-019-5290-4","article-title":"CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer","volume":"19","author":"Zhao","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/bs.apcsb.2023.02.001_bb0745","doi-asserted-by":"crossref","first-page":"40846","DOI":"10.18632\/oncotarget.8519","article-title":"The emerging roles and therapeutic potential of cyclin-dependent kinase 11 (CDK11) in human cancer","volume":"7","author":"Zhou","year":"2016","journal-title":"Oncotarget"}],"container-title":["Advances in Protein Chemistry and Structural Biology","Control of Cell Cycle & Cell Proliferation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876162323000135?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876162323000135?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,22]],"date-time":"2023-04-22T08:10:27Z","timestamp":1682151027000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876162323000135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"ISBN":["9780443158223"],"references-count":151,"URL":"https:\/\/doi.org\/10.1016\/bs.apcsb.2023.02.001","relation":{},"ISSN":["1876-1623"],"issn-type":[{"value":"1876-1623","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]}}}